Read this manager's filing book
Disclosed positions
B Group, Inc.: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- INVESCO QQQ TR
- Ticker
- Unresolved
- Class
- PUT
- Reported value
- $36,820,000
- Reported amount
- 50,000
- Unit
- SH
- Option
- Put
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001420506-26-001657Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| INVESCO QQQ TR | Unresolved | PUT | $36,820,000 | 50,000 | SH | Put |
| ADMA BIOLOGICS INC | ADMA | COM | $27,307,477 | 3,262,542 | SH | None |
| PALISADE BIO INC | PALI | COM | $23,855,856 | 11,414,285 | SH | None |
| NRX PHARMACEUTICALS INC | NRXP | COM NEW | $16,735,327 | 4,091,767 | SH | None |
| FAETH THERAPEUTICS INC | FTH | COM NEW | $15,254,225 | 610,169 | SH | None |
| TAYSHA GENE THERAPIES INC | TSHA | COM SHS | $12,261,786 | 1,800,556 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $11,127,415 | 33,237 | SH | None |
| CELLECTIS S A | CLLS | SPON ADS | $9,844,503 | 3,281,501 | SH | None |
| ZAI LAB LTD | ZLAB | ADR | $8,562,274 | 450,646 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $7,513,800 | 140,000 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $7,137,750 | 75,000 | SH | None |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | COM | $6,240,000 | 1,500,000 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $6,214,600 | 70,000 | SH | None |
| AURA BIOSCIENCES INC | AURA | COM | $5,426,125 | 764,243 | SH | None |
| ASSEMBLY BIOSCIENCES INC | ASMB | COM NEW | $4,828,401 | 175,706 | SH | None |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | COM NEW | $4,738,500 | 67,500 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $4,507,650 | 135,000 | SH | None |
| SIGHT SCIENCES INC | SGHT | COM | $3,656,900 | 970,000 | SH | None |
| FOGHORN THERAPEUTICS INC | FHTX | COM | $976,000 | 200,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 1 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.